FDA begins approval procedure of the first antibody biosimilar, Celltrion’s ‘Remsima’

Through its website, the U.S. Food and Drug Administration(hereinafter referring to FDA) announced that it is expected to hold the Arthritis Advisory Committee at the FDA White Oak Campus in Maryland and discuss matters about ‘Remsima,’ an autoimmune disease treatment, on the 9^th of February.

As an independent advisory organization, the advisory committee will provide general opinions about qu...